{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Mesoblast Limited"},"Symbol":{"label":"Symbol","value":"MESO"},"Address":{"label":"Address","value":"LEVEL 38, 55 COLLINS STREET, MELBOURNE, 3000, Australia"},"Phone":{"label":"Phone","value":"+61 396396036"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Australia and South Pacific"},"CompanyDescription":{"label":"Company Description","value":"Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others."},"CompanyUrl":{"label":"Company Url","value":"https://www.mesoblast.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Dagmar Rosa-Bjorkeson","title":"Chief Operating Officer"},{"name":"Eric A. Rose","title":"Executive Director & Chief Medical Officer"},{"name":"Paul Simmons","title":"Head-Research & New Product Development"},{"name":"Silviu Itescu","title":"Chief Executive Officer, Executive Director & MD"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}